2016 ACVIM Forum Research Abstract Program

All horses had improvements in clinical signs following treatment. No significant changes from baseline were observed in insulin or glucose parameters. Following 5 months of treatment, 12 of 16 (75%) horses T0ACTH decreased below normal range compared to 7/16 (44%) T10ACTH that decreased below the recommended reference range. Although all horses responded clinically, the T10ACTH in 9/16 (54%) horses remained positive. Even though T10ACTH did not decrease below reference range, the option to hold the treatment dosage at the same level is justifiable based on clinical sign improvement. Further long term studies in large numbers of horses should be conducted in horses with early PPID. Octreotide is a somatostatin analog that suppresses insulin secretion and we hypothesized that an octreotide response test (ORT) could be developed to detect insulin dysregulation (ID).